Press Coverage
Antoine Papiernik and Sylvain Gariel urge France to invest in vaccines
Related Deal lead
Antoine PapiernikFrance must invest much more if it wants to regain autonomy in vaccine production, or at least get sufficient access to vaccines made elsewhere, Sofinnova Partners Chairman Antoine Papiernik and Sylvain Gariel, co-founder of DNA Script, wrote in a guest editorial published in Les Echos.
Germany, the United States, Britain, Canada and Australia all have taken steps to pre-order or reserve production capacity of vaccines that may be sorely needed as the pandemic takes off again in the colder seasons.
Investment in health care has a double impact, the two leaders pointed out: mitigating the kind of drop in gross national product most countries experienced during the pandemic, and bolstering a sector with a large potential for profit.
Threats to health ignore borders, they stressed in the article published Sept. 13. France needs to act in concert with its European neighbors, diversify its commercial partners and focus on making France a truly innovative country when it comes to health care, they wrote in the leading French business daily.
Read the article in Les Echos (subscription required)
Related News
HighLife receives IDE approval to initiate US pivotal clinical study for treatment of mitral regurgitation
Johnson & Johnson completes acquisition of Shockwave Medical
Noema Pharma announces first patient dosed in Phase 2a Study of NOE-115, a first-in-class investigational therapy for the treatment of vasomotor symptoms and additional symptoms associated with menopause
May Health raises $25 million in Series B funding to advance development for Ovarian Rebalancing therapy
Johnson & Johnson to acquire Shockwave Medical